1,912,620 Shares in Recursion Pharmaceuticals, Inc. $RXRX Purchased by Nuveen LLC

Nuveen LLC bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,912,620 shares of the company’s stock, valued at approximately $10,118,000. Nuveen LLC owned approximately 0.48% of Recursion Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC raised its holdings in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company’s stock worth $38,000 after acquiring an additional 2,026 shares in the last quarter. NewEdge Advisors LLC raised its holdings in Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after acquiring an additional 2,387 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $54,000. San Luis Wealth Advisors LLC bought a new stake in Recursion Pharmaceuticals during the first quarter worth about $54,000. Finally, ADG Wealth Management Group LLC bought a new stake in Recursion Pharmaceuticals during the first quarter worth about $55,000. Institutional investors own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Needham & Company LLC restated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, July 8th. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an “equal weight” rating and a $5.00 price objective on the stock. Two analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $7.00.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $4.94 on Friday. The firm has a market cap of $2.14 billion, a P/E ratio of -2.78 and a beta of 0.93. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.02. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The business’s 50 day moving average is $5.46 and its 200-day moving average is $5.76.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The firm had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.Recursion Pharmaceuticals’s revenue for the quarter was up 33.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.40) EPS. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the transaction, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This trade represents a 5.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.